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Summary 
Priming with the major surface glycoprotein G of respiratory syncytial virus (RSV) 
expressed by recombinant vaccinia leads to strong Th2 responses and lung 
eosinophilia during viral challenge. We now show that DNA vaccination in 
BALB/c mice with plasmids encoding G attenuated RSV replication but also 
enhanced disease with lung eosinophilia and increased IL-4/5 production. 
However, formulating the DNA with PLG microparticles reduced the severity of 
disease during RSV challenge without significantly lessening protection against 
viral replication. PLG formulation greatly reduced lung eosinophilia and 
prevented the induction of IL-4 and IL-5 during challenge, accompanied by a less 
marked CD4+ T cell response and a restoration of the CD8+ T cell recruitment 
seen during infection of non-vaccinated animals. After RSV challenge, lung 
eosinophilia was enhanced and prolonged in mice vaccinated with DNA encoding 
a secreted form of G; this effect was virtually prevented by PLG formulation. 
Therefore, PLG microparticulate formulation modifies the pattern of immune 
responses induced by DNA vaccination boosts CD8+ T cell priming and attenuates 
Th2 responses. We speculate that PLG microparticles affect antigen uptake and 
intracellular routing, thereby influencing the outcome of DNA vaccination. 
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Introduction  
The introduction of novel and effective vaccines has contributed substantially to 
reducing or eliminating the burden of infectious diseases in human and animal 
populations. However, it has become clear that long-established pragmatic 
methods of vaccine development are failing to deliver vaccines against many 
important diseases and that new, immunologically informed, approaches need to 
be taken. A particularly important current trend is the introduction of new and 
specific adjuvants that not only augment protective immune responses, but also 
modify antigenic profiles to induce less pathogenic responses[1]. 
 
The recent success and licensing of vaccines containing virus-like particles (e.g. 
papilloma virus antigens; Gardasil, Merck & Co., Inc.) highlights the potential of 
microparticulate formulations to improve immunogenicity. It has been shown that 
synthetic cationic microparticles comprising cationic (polylactide-co-glycolide; 
PLG) microparticles have strong adjuvant effects and immune-stimulating 
properties[2] and to induce Th1- biased immune responses[3]. PLG can adjuvant 
the effects of DNA and ssRNA vaccination both in the mouse and in the monkey 
models[4],[5] and against viral antigens [6;7]. In studies of DNA vaccination 
against human immunodeficiency virus (HIV) gag and env in rhesus macaques, 
PLG formulation increased CD8+ T cell responses up to 1000 fold while boosting 
total antibody responses. The magnitude of the response to DNA vaccination with 
PLG DNA microparticles was found to be equivalent to that induced by the highly 
immunogenic recombinant gp120 protein formulated with the strong adjuvant 
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MF-59 [8]. However, the ability of PLG-DNA formulations to skew immune 
responses away from Th2 is less established and has not been tested in animal 
models of viral pulmonary infection. 
 
Respiratory syncytial virus (RSV) is an important common cold virus of man, and 
causes most cases of infantile bronchiolitis. Bronchiolitis is the commonest cause 
of infant hospitalisation in the western world, leading to admission of 1-2% of all 
children during the first year of life, and is associated with airway hyperreactivity, 
recurrent wheeze and the diagnosis of asthma during later childhood [9]. Asthma 
is characterised by a bias towards Th2 responses, associated frequently with 
airway eosinophilia. In a mouse model of RSV disease, sensitisation with 
recombinant vaccinia expressing the viral glycoprotein G primes for a strong Th2 
biased immune response that causes lung eosinophilia during intranasal infection 
with RSV[10]. G can be mutated at the second initiation codon to prevent 
secretion of the glycoprotein, and sensitisation with recombinant RSV expressing 
only the membrane bound (non-secreted) form of the G protein induces 
significantly less of an eosinophilic response during RSV challenge[11]. Similarly, 
challenge with genetically engineered RSV lacking the ability to produce secreted 
G causes less eosinophilia [11;12]. It has been shown that DNA-G immunization 
is able to produce significant neutralising and balanced antibody responses 
inducing both IgG1 and IgG2a subtypes, as well as protect against RSV infection 
in BALB/c mice [13;14], It can reduce mucin gene expression and lessen airway 
hyperresponsiveness [15]. Studies of DNA vaccination against RSV infection 
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have therefore shown promise, but have yet to translate into safe, immunogenic 
and effective vaccines for use in infants. 
 
Since DNA vaccine immunogenicity can be significantly improved by 
formulation with PLG microparticles in other situations, we formulated plasmids 
expressing various RSV proteins with PLG and tested for immunogenicity and 
pathogenicity in BALB/c mice. The plasmid encoding the viral glycoprotein G 
induced strong immune responses that were partially protective against viral 
challenge. However, vaccination with untreated DNA encoding G caused high 
levels of IL-5, IL-4 and eosinophil production during challenge; these effects were 
attenuated by formulation with PLG without significantly affecting antibody 
responses. Further, DNA encoding secreted G was even more prone to induce 
lung eosinophilia during challenge, an effect virtually abolished by DNA 
adsorption onto PLG. Therefore, DNA formulation with PLG microparticles 
modifies the host immune response, attenuating the pathogenic effects and 
modifying the host immune responses away from Th2 and lung eosinophilia 
without affecting the protection against viral replication.  
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Results  
DNA vaccination and RSV challenge 
Groups of 5 mice were immunized i.m. in the hind leg with 50μg of native DNA-
G, or 50μg of DNA-G adsorbed onto PLG microparticles, boosted similarly after 
4 weeks. Four weeks after boosting, mice were challenged by RSV infection i.n. 
Control groups were non-immunized, or had previously been infected with RSV 
i.n. (i.e. to produce protection against RSV challenge). In some experiments, 
control animals were immunized with empty PLG microparticles or with PLG 
coated with irrelevant DNA. 
  
Mice undergoing i.n. re-infection showed a transient weight loss on days 2 and 3, 
consistent with passive reaction to viral antigen exposure (Fig. 1A). However, 
such mice showed no evidence of viral replication on day 4 (Fig. 1B), consistent 
with protection against viral replication. Mice undergoing primary RSV infection 
showed no weight loss during the first 4 days (Fig. 1A), but developed a high viral 
load in the lungs (Fig. 1B). By day 7, these mice had lost 22% of the starting body 
weight (Fig. 1A), attributable to virus-induced lung pathology [10] 
 
Vaccination with DNA-G accelerated weight loss during the early stages 
following viral challenge but the maximum weight loss (day 7) was similar to 
mice undergoing primary RSV infection. The rate of onset and peak of weight 
loss was reduced by formulation of DNA with PLG (Fig. 1A), and PLG did not 
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significantly lessen the protective effect of vaccination on viral load during 
challenge (Fig. 1B).  
   
Immune responses to infection 
Although PLG formulation with DNA reduced the severity of weight loss on day 
4, the enhancement of lung cellularity at this time point was unaffected (Fig. 2A). 
However, lung eosinophilia was reduced by approximately 50% by addition of 
PLG (Fig. 2B), with virtual elimination of the IL-5 and IL-4 detected in the 
supernatant of isolated lung cells (Fig. 2D, 2F). There was also a similar effect on 
TNF-α levels detected (Fig. 2E). Despite this clear effect on IL-4 and IL-5, PLG 
had no effect on production of IFN-γ (Fig. 2C). Vaccination with DNA-G, with or 
without formulation with PLG, induced a significant RSV specific antibody 
response in the serum (Fig. 3A). Levels of total antibody and IgG isotypes were 
broadly similar after vaccination with DNA-G, regardless of the presence of PLG 
(Fig. 3B, C). Additionally, neutralizing ability of serum from mice immunized 
with either construct was similar (data not shown). In experiments where empty 
PLG or PLG/irrelevant DNA were used, immune responses mirrored those in 
primary RSV infection (data not shown). 
 
Analysis of the phenotype of cells recovered from the lungs of mice on day 8 after 
viral challenge showed that mice undergoing primary infection had responses 
dominated by CD8+ T cells, which outnumbered CD4+ T cells in ratio of 
approximately 1.5:1 (Fig. 4B). Vaccination with DNA-G boosted CD4+ T cell 
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responses and reduced CD8+ T cell responses, reversing this ratio. However, 
formulation of the DNA with PLG caused more balanced responses with 
CD8+:CD4+ T ratio 1.3:1 (Fig. 4).   
 
Immune responses to secreted antigen 
The amino acid sequence of the RSV G protein can be manipulated to induce 
expression of a truncated protein that is purely secreted (Gsec), mimicking a form 
of the RSV G protein naturally produced early after RSV infection. To test the 
effects of DNA-Gsec in this system, mice were similarly vaccinated with 
constructs with or without formulation to PLG.   
 
Weight loss following RSV challenge mirrored that observed after vaccination 
with the standard plasmid encoding wild type G, and formulation to PLG reduced 
the severity of disease during RSV challenge. However, PLG formulation had no 
effect on the peak of weight loss or cellularity in the BAL. Vaccination with 
DNA-Gsec caused marked lung eosinophilia on day 4 (Fig. 5D), and this 
eosinophilia persisted and actually increased on day 8 (Fig. 5E), although RSV 
has been cleared from the lung by this time point (data not shown). Remarkably, 
PLG formulation of DNA-Gsec greatly reduced eosinophilia on day 4 (Fig. 5D) 
and abolished the persistent and enhanced eosinophilia on day 8 (Fig. 5E). This 
was associated with a significant enhancement of CD8 T cell responses on day 8 
(Fig. 5G).  
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Cytokine analysis revealed exactly the same pattern as in experiments where wtG 
was used for DNA and DNA/PLG formulations (data not shown).
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Discussion  
Although DNA vaccination has been successful in some experimental settings, 
improved formulations and immunogenicity are required before it can be 
successfully applied in man. We show here that plasmid DNA encoding the RSV 
glycoprotein G is immunogenic in mice, but that it also produces a Th2 biased 
response with lung eosinophilia during challenge. This effect is particularly 
marked with plasmid encoding the secreted form of G. In either case, formulation 
of DNA with PLG microparticles greatly attenuated the pathogenic effects of 
DNA vaccination without significantly lessening partial antiviral protection. This 
represents a significant advance, suggesting that microparticulate formulation can 
be used to manipulate host immune responses to DNA vaccination. 
 
The induction of significant eosinophilia during RSV challenge of DNA 
vaccinated mice is consistent with other studies demonstrating that the G protein 
can sensitise for eosinophilia [10;11;16]. However, there are conflicting results 
from studies using DNA plasmids encoding G as a vaccine.  Balanced Th1/Th2 
responses accompanied by significant protection against RSV challenge and an 
absence of pulmonary eosinophilia have been reported in some settings [13;14]. 
However, sensitisation with DNA encoding G or F are both reported to induce 
BAL eosinophilia [17]. Differences in DNA expression vectors, route of 
immunization, dose and vaccination schedule may influence these different 
outcomes. 
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The mouse model of RSV is ideal for studies of this type, in that the immune 
response can be selectively biased towards Th1 or Th2 immunity, to favour 
cytotoxic T cell responses or antibody production. In this case, we chose to study 
immune responses that favour Th2 cytokine production and lung eosinophilia, 
allowing us to study the effects that counter this pattern of immunity. We 
reasoned that DNA formulation with PLG microparticles might lead to 
phagocytosis by antigen presenting cells, and that the intrinsic adjuvant properties 
of DNA (due to un-methylated CpG motifs) might significantly alter the immune 
response in ways that would inhibit pathogenic effects of vaccination. The 
presence of CpG motifs is associated with an increase in IL-12 mRNA expression 
resulting in a Th1-biased microenvironment [18]. CpG motifs present in bacterial 
DNA specifically bind Toll-like receptor-9 (TLR-9) located on the internal 
membranes of several cell types including B cells, macrophages and dendritic 
cells. Such interactions activate the Toll/interleukin (IL)-1-recptor signalling 
pathway leading to production of pro-inflammatory cytokines including the Th1-
polarising cytokine, IL-12. Furthermore, physical trauma due to the skin 
following needle injection leads to an increase in TLR-9 mRNA expression [19], 
enhancing the response to CpG motifs [20]. Therefore, immunization with PLG 
microparticles that delivers DNA directly to endosomes would favour enhanced 
Th1 responses, counteracting the intrinsic Th2 bias induced by immunization with 
RSV glycoprotein G. We and others have shown that CD8+ cells producing IFN-γ 
attenuate eosinophilia by inhibiting Th2 responses [21;22]. This effect may result 
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from PLG facilitating entry of material into the cytosol, favouring presentation via 
the endogenous class I pathway [23;24].  
 
Our results show that formulation with PLG boosts CD8+ responses in the lung 
during subsequent RSV infection, suggesting that PLG deviates responses towards 
MHC class I antigen ‘endogenous’ presentation to CD8 T cells. We suggest that 
PLG may promote direct uptake of DNA into APCs, resulting in endogenously 
expressed protein that is processed and presented by the MHC class I pathway for 
the induction of CD8+ T cells [8;25;26]. 
  
Intramuscular injection of DNA primarily targets myocytes, where antigen is 
expressed before release and uptake by APCs. APCs may also be directly 
transfected, but this is thought to be a less important mode of action. PLG forms a 
depot at the site of injection lasting for at least 7 days, accompanied by expression 
of encoded antigen [27]. The mechanical trauma of injection and presence of PLG 
recruits phagocytes and activates antigen presenting cells at the injection site. We 
speculate that PLG may not only affect the DNA which is co-administered, but 
that residual PLG could also influence the uptake of antigen synthesised by non-
professional antigen presenting cells. However, our data does not allow us to 
differentiate between these possibilities. Although our findings demonstrate the 
ability of PLG formulation to modify responses to DNA vaccination, we 
emphasise that this type of vaccine is unlikely to be effective in children in 
preventing RSV disease, and that other types of vaccine (live attenuated or 
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mucosal vaccines, for example) may offer greater practical hope in preventing 
RSV infection in man. 
 
To conclude, DNA vaccines formulated with PLG avoid the enhanced disease 
seen after simple DNA vaccination by modulating pathogenic Th2 responses and 
by enhancing Th1 effects. This may represent an enhancement of the adjuvant 
activity of CpG motifs naturally contained within DNA, or be caused by effects 
on antigen processing and presentation. PLG formulation could therefore improve 
the outcome of vaccination, leading to greater vaccine efficacy and safety. These 
effects might be particularly beneficial in neonatal vaccination (a time at which 
RSV vaccines should ideally be given), since newborn children show an inherent 
deficiency of Th1 responses to antigenic challenge. 
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Materials and Methods 
DNA plasmids  
The wild type sequence of the G protein of RSV strain A2, was cloned into the 
SalI and XbaI restriction sites of the eukaryotic expression vector pCMVKm2 that 
contains the cytomegalovirus (CMV) immediate-early enhancer/promoter and 
bovine growth hormone (bGH) terminator (Chiron Corporation, Emeryville) [28], 
resulting in the plasmid pCMVKm2_wtG; from hereon in referred to as DNA-G. 
The plasmid was grown in Escherichia coli strain XL-1 blue (Stratagene), purified 
using a Qiagen Endofree Plasmid Giga kit (Qiagen) and resuspended in nuclease 
free water (Promega). 
 
Preparation and formulation with PLG microparticles 
Cationic microparticles of about 1μm diameter were prepared using a modified 
solvent evaporation procedure, as described [29]. A primary emulsion of PLG 
polymer (RG504) was homogenized at 6% w/w with dichloromethance (DCM) in 
the presence of tris EDTA using an IKA homogeniser. This preparation was then 
added to a secondary emulsion of purified water containing 0.015% 
cetyltrimethylammonium bromide (CTAB) resulting in 1% CTAB w/w PLG. The 
resulting water-in-oil-in-water emulsion was then stirred overnight to allow 
evaporation of DCM. Microparticles were then filtered and DNA adsorbed by 
adding a 2mg/ml solution drop wise at approximately 100μl/min. Formulations 
were lyophilised for storage prior to use. Physical characteristics were examined 
as previously described [29]. 
Submission to Vaccine 
 Page 15 16/11/2007 
Immunization of mice  
Groups of five 6 to 8 week old female BALB/c mice (Harlan, Berkhamsted, UK) 
were housed under pathogen-free conditions. All procedures were subjected to 
ethical review and licensed by the Home Office, UK. A total of 50μg of either 
PLG/DNA-G formulation or naked DNA-G was administered in a total of 100μl 
volume between each hind leg by needle injection. All mice were boosted with the 
same dose of vaccine after 4 weeks. A further 4 weeks after the second dose, all 
mice were anaesthetized and given 100μl 5x105 pfu RSV (strain A2) via the nose. 
The virus was grown and assayed for infectivity on Hep-2 cells [21]. All stocks 
were free of mycoplasma contamination. 
Quantification of viral RNA 
RNA was extracted from the lung using RNA STAT-60 (Tel-test Inc.) and cDNA 
was generated with random hexamers using an Omniscript RT-kit (Qiagen). PCR 
specific for RSV L gene was performed at 50°C for 2 min and 95°C for 10 min 
followed by 40 two-step cycles (95°C for 15s, 60°C for 1min) with Quantitech 
Probe PCR kit (Qiagen) and 900 nM forward primer (5’- 
GAACTCAGTGTAGGTAGAATGTTTGCA – 3’), 900 nM reverse primer (5’ – 
TTCAGCTATCATTTTCTCTGCCAAT – 3’) and 100 nM probe (5’ – FAM – 
TTTGAACCTGTCTGAACATTCCCGGTT – TAMRA – 3’). Copy number of 
the L gene was determined from standard curves against PCDNA3 plasmid vector 
containing a fragment of the RSV L-gene. PCR amplifications were measured in 
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real time using ABI 7000 (Applied Biosystems) and analyzed using Sequence 
Detections Systems (v1.1). 
 
RSV-specific antibody ELISA 
ELISA antigen was prepared by infecting HEp-2 cells with RSV strain A2 at 
1 PFU/cell. When a significant cytopathic effect was observed, infected cells were 
harvested, centrifuged at 400×g, resuspended in 3 ml distilled water and then 
subjected to 2 min of sonication (Ultrawave Ltd., Cardiff, GB); 50 μl aliquots 
were stored at -20°C until required. Microtiter plates were coated overnight with 
100 μl of a 1:500 dilution of either RSV antigen or HEp-2 cells alone. After 
blocking with PBS/1% BSA for 1 h, dilutions of test samples (diluted in PBS 
containing 0.2% BSA 0.01% Tween) were added for a further 2 h at 37oC. Bound 
antibody was detected using peroxidase-conjugated rabbit anti-mouse Ig and O-
phenylenediamine as a substrate (Sigma Fast OPD tablets). For isotype specific 
antibody determination, bound antibody was detected with either biotinylated 
anti-IgG1 or IgG2a as required, followed by extravidin peroxidase (Sigma) before 
colour development with OPD. Colour development was stopped with 2 M H2SO4, 
and optical densities were read at 490 nm. The level of RSV-specific antibody 
was determined by subtracting the absorbance obtained from samples incubated 
on RSV antigen-coated wells from the same sample incubated on HEp-2-coated 
wells. 
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ELISA for interleukins  
IL-4, IL-5, TNFα and IFNγ were measured in supernatants of homogenized lung 
cells by ELISA performed according to the manufacturer’s instructions (Becton 
Dickinson-Pharmingen). Briefly, ELISA plates (Nunc) were coated with a capture 
antibody diluted 1:500 and left overnight at 4°C. The wells were then washed with 
PBS–0.05% Tween 20 and blocked with PBS–1% BSA for 2 h at room 
temperature. Samples or standard were added at 100μl per well and left overnight 
at 4°C. Bound cytokine was detected with a biotinylated anti-cytokine antibody, 
Avidin-horseradish peroxidase, and OPD. Colour development was stopped with 
2 N H2SO4, and optical density read at 490 nm. The concentration of cytokine in 
each sample was determined from a standard curve.  
Cell surface markers 
Lung cells were plated at 106 cells/ml in FACS staining buffer (PBS 1%BSA 
0.1% Azide). Cells were then blocked with Fc block (CD16/CD32 antibody from 
Pharmingen) prior to staining with fluorescently labelled antibody against surface 
markers (CD3-FITC, CD-APC, CD8-PECy5, all from Pharmingen) for 30 min on 
ice and then fixed for 20 min at room temperature with 2% formaldehyde. Cells 
were then analyzed on a BD-LSR flow cytometer collecting data on at least 
50,000 events. 
Statistical analysis 
Differences between groups were analysed using one-way ANOVA followed by 
the Tukey test using GraphPad Prism (Version 4.0). For multiple comparisons 
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between groups, two-way ANOVA was performed followed by the Bonferroni 
post test. P values <0.05 were considered statistically significant.
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 Figure legends 
 
Figure 1: Effects of immunization on protection from RSV-induced weight 
loss. Mice were immunized twice i.m. with either PLG/DNA-G (black circles) or 
DNA-G (white circles) 4 weeks apart; control mice received either nothing (1° 
RSV: black squares) or i.n. RSV once (2° RSV: black triangles). 4 weeks after the 
second dose, all mice were challenged i.n. with RSV. A) Change in body weight 
post infection. B) RSV L gene copy number per lung as measured by Taqman RT-
PCR. Data points represent the mean of n=5 ± SEM: BLD, below limit of 
detection; N/S, not significant. 
 
Figure 2: PLG/DNA-G induces a weaker Th2 response than naked DNA-G. 
Immunized mice were challenged with RSV. Four days later, mice were sacrificed 
and BAL performed. The total viable cell number was calculated by trypan blue 
exclusion (A) and the percentage of eosinophils calculated from H&E stained 
cytospin slides (B). Lungs were removed, mashed and supernatants processed for 
cytokine ELISA to detect IFN-γ (C), IL-5 (D), TNF-α (E) and IL-4 (F). Data  
shown as mean +/- SEM. 
 
Figure 3: Effect of immunization on the humoral response to infection.  
Eight days after RSV challenge, mice were sacrificed and serum tested for viral 
antibody. Total RSV-specific IgG (A), IgG1 (B) and IgG2a (C) isotypes were 
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measured by ELISA. Data show the average and standard error for optical 
densities obtained after development with OPD for serum diluted 1 in 400. 
 
Figure 4: PLG/DNA-G induces a stronger CD8 response than naked DNA-G. 
Eight days after RSV challenge, mice were sacrificed and lungs taken for FACS 
analysis. Cells were stained with fluorochrome-conjugated antibodies to CD4, 
CD8 and CD3. Positive events were recorded on a BD-LSR and cells gated on 
lymphocytes based on forward and side scatter characteristics. Individual 
representative dot plots are shown for each group (A) from which the group mean 
and standard error was determined (B). 
 
Figure 5: Effects of PLG formulation on immune responses to DNA encoding 
secreted RSV G protein. Mice were immunized twice i.m. with either 
PLG/DNA-Gsec or DNA-Gsec 4 weeks apart; control mice received either 
nothing (1° RSV) or i.n. RSV once (2° RSV). Four weeks after the second dose 
all mice were challenged i.n. with RSV. Four and eight days after RSV challenge 
mice were culled and BAL and lungs collected. (A) Change in body weight post 
infection. Mice receiving PLG/DNA-Gsec  (black diamonds) or DNA-G sec 
(white squares), 1° RSV (black circles) and 2° RSV( black squares) (B) Cell 
counts in BAL, 4 and (C) 8 days after challenge, (D) eosinophilia in BAL 4 and 
(E) 8 days after challenge, (F) CD8 T cells in lung 4 and (G) 8 days after 
challenge. Bars represent mean of n=5 mice ± SEM. 
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